삼익제약 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 권영이, was filed 06 Jul 2026.
삼익제약: what insiders have been doing
삼익제약 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Between 2 November 2025 and 2 November 2026, 6 insiders published 13 filings.
On the market, 5 insiders bought (7 purchases totalling €76k) while 3 insiders sold (6 sales totalling €90k). The totals do not cover 11 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 2 senior executives, 1 major shareholder and 1 board member among the declarants. The largest single trade was a sale of €90k by 권영이, published on 4 June 2026, equal to 0.30% of the market capitalisation.
Compared with its exchange (2,655 companies, median 7 filings), a count of 13 filings is above the norm. Our records for 삼익제약 go back to 2025, with 13 purchases and 6 sales on the open market in total.
The most recent open-market purchase was published on 6 July 2026, 125 days ago.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySale+3 other insiders
Since the insiders bought
- -35.4%Entry ₩10,960 · Close 30 Oct 2026 ₩7,080
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 20,000 sharesShareKRXDART:20260923000239
- 60,000 sharesShareKRXDART:20260706000106Canonical exit: 4 Oct 2026 (T+90)
- 3,257 sharesKRXDART:20260706000110Canonical exit: 4 Oct 2026 (T+90)
- 192,303 sharesKRXDART:20260625000554
- 15,000 sharesShareKRXDART:20260608000098
- 49,700 sharesKRXDART:20260608000101
- 21,932 shares@ ₩7,163.26550.30% mcap54.0% of flowShareKRXDART:20260604000155
- 13,068 sharesShareKRXDART:20260519000026
- 25,000 shares@ ₩5,310.000.26% mcap46.0% of flowShareKRXDART:20260326000891Canonical exit: 24 Jun 2026 (T+90)
- 2,000 sharesShareKRXDART:20260114000004Canonical exit: 14 Apr 2026 (T+90)
- 5,500 sharesShareKRXDART:20260114000006Canonical exit: 14 Apr 2026 (T+90)
- 2,000 sharesShareKRXDART:20260114000008Canonical exit: 14 Apr 2026 (T+90)
- 25,000 sharesShareKRXDART:20260106000712Canonical exit: 7 Apr 2026 (T+90)
- 674,345 sharesKRXDART:20251031000309Canonical exit: 25 Jan 2026 (T+90)
- 6,113,800 sharesKRXDART:20251031000478Canonical exit: 25 Jan 2026 (T+90)
- 2,000,000 sharesShareKRXDART:20251031000498Canonical exit: 29 Jan 2026 (T+90)
- 1,000,000 sharesShareKRXDART:20251031000541Canonical exit: 29 Jan 2026 (T+90)
- 1,066,950 sharesShareKRXDART:20251031000530Canonical exit: 29 Jan 2026 (T+90)
- 932,000 sharesShareKRXDART:20251031000553Canonical exit: 29 Jan 2026 (T+90)
20 of 20 declarations
About 삼익제약
Samik Pharmaceutical is a company in the health and pharmaceutical sector, listed on the XKRX exchange. It focuses on the development and distribution of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
